BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04421820 |
Recruitment Status :
Recruiting
First Posted : June 9, 2020
Last Update Posted : October 22, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma | Drug: BOLD-100 in combination with FOLFOX Chemotherapy | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours |
Actual Study Start Date : | August 28, 2020 |
Estimated Primary Completion Date : | December 31, 2021 |
Estimated Study Completion Date : | March 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Gastric Cancer |
Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks |
Experimental: Pancreatic Cancer |
Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks |
Experimental: Colorectal Cancer |
Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks |
Experimental: Cholangiocarcinoma |
Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks |
- Incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Incidence of serious adverse events (SAE) and suspected unexpected serious adverse reactions; [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Incidence of dose-limiting toxicities (DLT) [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Incidence of clinically significant changes or abnormalities from Physical Examinations, ECGs, Vital Signs, Laboratory Results (chemistry, hematology, coagulation, urinalysis), Eastern Cooperative Oncology Group (ECOG) performance status [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Progression Free Survival (PFS); Overall Response Rate (ORR); Overall Survival (OS) [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Standard PK parameters including Cmin [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Baseline GRP78 biomarker levels (Counts/mL) [ Time Frame: Baseline ]
- Changes in GRP78 biomarker levels during treatment (Counts/mL) [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Standard PK parameters including Cmax [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Standard PK parameters including TSS [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Standard PK parameters including CSS [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
- Standard PK parameters including Vdss [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Be 18 years or older.
- Be male or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol (see Table 12. Acceptable Contraceptive Methods.)
- Histologically and/or cytologically confirmed gastrointestinal tumours that are metastatic or unresectable, and have received at least one line of chemotherapy in the metastatic setting (in the dose escalation phase only). For the dose expansion phase, the setting will vary based on the malignancy. Colorectal cancer: Patients must have received at least 1 prior line of therapy prior to enrollment in this study. Pancreatic cancer: Patients must have received at least 1 prior line of therapy. Gastric cancer: Patients who have not received prior treatment may be included in this study. Cholangiocarcinoma: Patients must have received at least 1 prior line of therapy (with gemcitabine-based chemotherapy).
- Have measurable disease according to RECIST v1.1 (at least one measurable lesion).
- Have an anticipated survival of at least 16 weeks.
- Be ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.
-
Have adequate organ function, defined as:
- Hematologic: ANC ≥ 1.5 x 109/L, Hgb ≥ 9.0 g/dL and platelet count ≥ 100 x 109/L
- Hepatic: total bilirubin ≤ 1.5 x ULN; transaminases ≤ 2.5 x ULN (may be up to 5 x ULN if clearly due to liver metastases), ALP ≤ 2.5 x ULN
- Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min.
c. Urine protein is 0, trace, or +1 on dipstick urinalysis, or < 1.0 gram on 24-hour urine protein analysis
- Be on stable doses of any drugs that may affect hepatic drug metabolism or renal drug excretion (e.g., non-steroidal anti-inflammatory drugs, corticosteroids, barbiturates, diphenylhydantoin, narcotic analgesics, probenecid). Such drugs should not be initiated while the subject is participating in this study or have been initiated within 30 days beforehand. Whenever possible, narcotic analgesic doses should be stable within 30 days prior to study entry and during the first cycle of therapy.
- Resolved acute effects of any prior therapy to baseline severity or grade ≤1 CTCAE 5.0 except for adverse events not constituting a safety risk by investigator judgment (such as alopecia)
- Able to take oral medications (for pre-medications and supportive management)
- Understand and be able, willing, and likely to fully comply with study procedures and restrictions.
- Be fully informed about their illness and the investigational nature of the study protocol, and sign a REB-approved Informed Consent Form (ICF).
Exclusion Criteria:
- Neuropathy > grade 2
- Previous intolerance to or significant reaction secondary to fluorouracil or oxaliplatin
- Cerebrovascular accident within the past 6 months.
- History or presence of central nervous system (CNS) metastasis or leptomeningeal tumours as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam.
- Any serious medical conditions that might be aggravated by treatment or limit compliance. This includes, but is not limited to uncontrolled psychiatric disorders, serious infections, active peptic ulcer disease and bleeding diathesis
-
Any history of serious cardiac illness including (but not confined to):
- Previous or active myocardial infarction < 6 months
- Congestive cardiac failure (NYHA III or IV)
- History of unstable angina pectoris < 6 months
- Recent coronary artery bypass grafting < 6 months
- Uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg)
- Ventricular arrhythmia < 6 months
- Left ventricular ejection fraction (LVEF) < 50% as measured either by radionuclide angiography or echocardiogram
- QTc interval > 470 msec
- Hemoptysis, cerebral, or clinically significant gastrointestinal hemorrhage in the past 6 months
- Any other known malignancy within 3 years (with the exception of non-melanoma skin cancer that had undergone curative treatment, cervical cancer in situ, or ductal/lobular carcinoma in situ of the breast that has underwent local treatment
- Active gastrointestinal tract disease with malabsorption syndrome.
- Non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease.
- Treatment with radiation therapy or surgery within one month prior to study entry.
- Recent history of weight loss > 10% of current body weight in past 3 months.
- Current (within 1 week of the start of the study) or regular use of any medication (including OTC, herbal or homeopathic preparations) that could affect (improve or worsen) the cancer being studied, or could affect the action or disposition of BOLD-100, or its clinical or laboratory assessment, e.g., Coumadin therapy, due to high competitive protein binding. Subjects taking ANY supplemental IRON, i.e., therapeutic or as part of a multivitamin regimen, are excluded from this study, whether prescribed or self-medicated.
- HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
- Any condition potentially decreasing compliance to study procedures. Concurrent use of another investigational therapy or anti-cancer therapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04421820
Contact: Michelle Jones | 604-262-9899 | clinical@bold-therapeutics.com | |
Contact: Jim Pankovich | 604-262-9934 | jp@bold-therapeutics.com |
Canada, Alberta | |
Cross Cancer Institue | Recruiting |
Edmonton, Alberta, Canada, T6G1Z2 | |
Contact: Diane Arndt 780-989-8157 diane.arndt2@albertahealthservices.ca | |
Canada, Ontario | |
Juravinski Cancer Centre | Recruiting |
Hamilton, Ontario, Canada, L8V 5C2 | |
The Ottawa Hospital Cancer Centre | Recruiting |
Ottawa, Ontario, Canada, K1H 8L6 | |
Contact: Matthew MacDonald 613-737-7700 ext 70955 matmacdonald@ohri.ca | |
Princess Margaret Cancer Centre | Recruiting |
Toronto, Ontario, Canada, M5G 2M9 | |
Contact: Grainne O'Kane (416) 946-4501 ext 4853 Grainne.O'Kane@uhn.ca | |
Canada, Quebec | |
Jewish General Hospital | Recruiting |
Montreal, Quebec, Canada, H3T 1E2 | |
Contact: Angelica Lara 514-340-8222 ext 24624 angelica.bonilla.ccomtl@ssss.gouv.qc.ca | |
McGill University Health Centre Glen Site | Recruiting |
Montréal, Quebec, Canada, H4A 3J1 | |
Contact: Ronald Pelissier 514-934-1934 ext 61834 ronald.pelissier@muhc.mcgill.ca |
Responsible Party: | Bold Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT04421820 |
Other Study ID Numbers: |
BOLD-100-001 |
First Posted: | June 9, 2020 Key Record Dates |
Last Update Posted: | October 22, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Cholangiocarcinoma Neoplasms Adenocarcinoma |
Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |